I-Mab (NASDAQ:IMAB) — Market Cap & Net Worth
Market Cap & Net Worth: I-Mab (IMAB)
I-Mab (NASDAQ:IMAB) has a market capitalization of $456.45 Million ($456.45 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12813 globally and #3158 in its home market, demonstrating a 0.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying I-Mab's stock price $3.96 by its total outstanding shares 115266053 (115.27 Million). Also see I-Mab (IMAB) total assets for a full breakdown of the balance sheet.
I-Mab Market Cap History: 2020 to 2025
I-Mab's market capitalization history from 2020 to 2025. Data shows change from $5.43 Billion to $456.45 Million (-17.55% CAGR). Also see I-Mab (IMAB) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
I-Mab is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.02% | #346 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1265 of 3165 |
Weight: I-Mab's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
I-Mab Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how I-Mab's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check IMAB stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
48.82x
I-Mab's market cap is 48.82 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $5.43 Billion | $1.54 Billion | $470.92 Million | 3.52x | 11.54x |
| 2021 | $5.46 Billion | $88.03 Million | -$2.33 Billion | 62.06x | N/A |
| 2022 | $481.81 Million | $-10.70 Million | -$2.51 Billion | -45.04x | N/A |
| 2023 | $219.01 Million | $4.49 Million | -$1.47 Billion | 48.82x | N/A |
Competitor Companies of IMAB by Market Capitalization
Companies near I-Mab in the global market cap rankings as of September 18, 2026. Review IMAB goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to I-Mab by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
I-Mab Historical Marketcap From 2020 to 2025
Between 2020 and today, I-Mab's market cap moved from $5.43 Billion to $ 456.45 Million, with a yearly change of -17.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $456.45 Million | +365.88% |
| 2024 | $97.98 Million | -55.26% |
| 2023 | $219.01 Million | -54.55% |
| 2022 | $481.81 Million | -91.18% |
| 2021 | $5.46 Billion | +0.51% |
| 2020 | $5.43 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of I-Mab was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $456.45 Million USD |
| MoneyControl | $456.45 Million USD |
| MarketWatch | $456.45 Million USD |
| marketcap.company | $456.45 Million USD |
| Reuters | $456.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About I-Mab
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment o… Read more